Name | Bifendate |
Synonyms | Bifendate Bifendatatum Bifendatatum CP BifendatatuM API Biphenyldimethylesterate dimethyl 7,7'-dimethoxy-4,4'-bi-1,3-benzodioxole-5,5'-dicarboxylate 4'-bi-1,3-benzodioxole)-5,5'-dicarboxylicacid,7,7'-dimethoxy-(dimethyles DiMethyl 7,7'-diMethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate dimethyl4,4'-dimethoxy-5,6,5',6'-bis(methylenedioxy)biphenyl-2,2'-dicarboxyl [4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylicacid, 7,7'-diMethoxy-, 5,5'-diMethyl ester |
CAS | 73536-69-3 |
EINECS | 1806241-263-5 |
InChI | InChI=1/C20H18O10/c1-23-11-5-9(19(21)25-3)13(17-15(11)27-7-29-17)14-10(20(22)26-4)6-12(24-2)16-18(14)30-8-28-16/h5-6H,7-8H2,1-4H3 |
Molecular Formula | C20H18O10 |
Molar Mass | 418.35 |
Density | 1.390±0.06 g/cm3(Predicted) |
Melting Point | 179-181 °C |
Boling Point | 606.9±55.0 °C(Predicted) |
Flash Point | 265.9°C |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 1.12E-14mmHg at 25°C |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | 2-8°C(protect from light) |
Refractive Index | 1.579 |
MDL | MFCD01751431 |
Use | Anti-hepatitis drugs for the treatment of chronic persistent hepatitis, chronic active hepatitis and other diseases |
Reference Show more | 1. [IF=3.205] Zhibin Wang et al."Simultaneous determination of cucurbitacin B and cucurbitacin E in rat plasma by UHPLC-MS/MS: A pharmacokinetics study after oral administration of cucurbitacin tablets."J Chromatogr B. 2017 Oct;1065-1066:63 |
Overview | bifendate is an enzyme-lowering drug developed in China for the treatment of hepatitis with high biological activity, can reduce serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, enhance the detoxification function of the liver, has the effect of anti-liver cell necrosis, chemotherapy drugs such as methotrexate, toxic hepatitis caused by 5-fluorouracil has obvious therapeutic effect, and the toxicity is very low, no teratogenic, mutagenic effect, pharmacological experiments confirmed that bifendate has certain anticancer activity. Clinical for persistent, chronic hepatitis and serum aminotransferase continued to increase in patients, can also be used for patients with sustained elevation of alanine aminotransferase caused by drugs. Bifendate is a new drug discovered in the process of studying schisandra chinensis, and is also an intermediate product of synthetic schisandra chinensis C, it was a single lignan compound with pharmacological activity isolated from the extract of schisandra chinensis kernel by Beijing Institute of Medicine in the 1970s, Α-biphenyl diester (α-DDB) was synthesized for the first time, and two isomers, β-biphenyl diester (β-DDB) and γ-biphenyl diester (γ - DDB) were obtained, the structure of the β-DDB biphenyl moiety is consistent with that of the natural product schisandra chinensis. |
effect | has the effect of reducing alanine aminotransferase, for patients with hepatitis or drug-induced elevation of serum alanine aminotransferase, the enzyme reduction effect is significant and rapid, and the adverse reactions are mild and less, and the curative effect is better than that of the commonly used hepatitis drugs. The enzyme-reducing effect of this product gradually increased with the extension of the course of treatment. The single alanine aminotransferase high effect is better. The curative effect of HBsAg negative is obvious than positive. It can improve the main symptoms of hepatitis, but has no effect on the changes of liver and spleen. |
Use | 1. For chronic persistent hepatitis with long-term increase of alanine aminotransferase. 2. For single alanine aminotransferase increased, no other abnormal liver function. 3. For chemical drug-induced elevation of alanine aminotransferase. anti-hepatitis drugs for the treatment of chronic persistent hepatitis, chronic active hepatitis and other diseases |
synthesis method | Methyl gallate was obtained by refluxing gallic acid with methanol (CH3OH) under the catalysis of concentrated sulfuric acid (conc.H2SO4). Methyl gallate was dissolved in Borax aqueous solution, and dimethyl sulfate ((CH3)2SO4) and sodium hydroxide (NaOH) solution were added dropwise to obtain methyl 3, 4-dihydroxy-5-methoxybenzoate. Further, it was refluxed with dichloromethane (CH2Cl2), anhydrous potassium carbonate (K2CO3) and N,N-dimethylformamide (DMF) to give methyl 3, 4-methylenedioxy-5-methoxybenzoate. Finally, bromination (Br2) was carried out in chloroform (CHCl3) to give methyl 2-bromo-3, 4-methylenedioxy-5-methoxybenzoate, which was prepared by Urman reaction. Figure 1 is the synthesis of bifendate |
pharmacokinetics | The oral absorption of this product is about 30%, and the first effect on the liver is obvious. About 70% was excreted from feces within 24h. The bioavailability of dripping pills is 1.25~2.37 times that of tablets. (2015-12-28) |
contraindication | 1. Pregnant and lactating women. |
note | 1. ALT may be increased in a small number of patients during medication, and may be reduced by increasing the dose. After drug withdrawal, some patients had rebound ALT, but continued medication was still effective. 2. Individual patients in the course of medication may appear jaundice and disease progression, should be discontinued. 3 patients with chronic hepatitis and elderly patients with caution. |
drug interaction | inosine can reduce the enzyme rebound phenomenon of this product. |